Cite
HARVARD Citation
Pirker, R. et al. (2019). From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer. ESMO open. 4 (5), p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Pirker, R. et al. (2019). From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer. ESMO open. 4 (5), p. . [Online].